NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
Jenna H BurtonChristina MazckoAmy LeBlancJoseph M CoveyJiuping JiRobert J KindersRalph E ParchmentChand KhannaMelissa PaoloniSue LanaKristen WeishaarCheryl LondonWilliam KisseberthErika KrickDavid VailMichael ChildressJeffrey N BryanLisa BarberE J EhrhartMichael KentTimothy FanKelvin KowNicole NorthrupHeather Wilson-RoblesJoseph TomaszewskiJulianne L HolleranMiguel MuzzioJulie EisemanJan H BeumerJames H DoroshowYves PommierPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
These results demonstrate proof-of-mechanism for indenoisoquinoline TOP1 inhibitors supporting their further clinical development. They also highlight the value of the NCI Comparative Oncology Program (https://ccr.cancer.gov/Comparative-Oncology-Program) for evaluating novel therapies in immunocompetent pets with cancers.